Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Protalix BioTherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Protalix BioTherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Schwartz Aharon | Director | 7,500Indirect | Sep 9, 2026 | 1 |
| Naos Yaron | Sr. VP & COO | 225,817Indirect | Sep 4, 2026 | 1 |
| Melincoff Gwen A | Director | 7,500Indirect | Sep 4, 2026 | 1 |
| Elze Christian | Director | 7,500Indirect | Sep 4, 2026 | 1 |
| Boudes Pol F | Director | 7,500Indirect | Sep 4, 2026 | 1 |
| Bar-Shalev Amos | Director | 0 | Sep 4, 2026 | 2 |
| Bashan Dror | PRESIDENT AND CEO | 188,516 | Sep 4, 2026 | 2 |
| Ben Zvi Shmuel | Director | 7,500Indirect | Sep 4, 2026 | 1 |
| Forster Eliot | Director | 7,500Indirect | Sep 4, 2026 | 1 |
| Rubin Eyal | Sr. VP and CFO | 660,909Indirect | Nov 5, 2024 | 0 |
| Hayon Yael | VP, Research & Development | 35,115Indirect | Aug 17, 2023 | 0 |
| Bronfeld Zeev | Director | – | Sep 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2022 (view filing) | Apr 11 | 2 days | Bashan DrorPresident and CEO | PPurchase | +68.0K | $1.50 | +$102.0K | New position68.0K after | |
| Jan 5, 2023 (view filing) | Jan 3 | 2 days | Schwartz AharonDirector | PPurchase | +110.0K | $1.42 | +$156.2K | +171.9%174.0K after | |
| Oct 20, 2023 (view filing) | Oct 19 | 1 day | Bashan DrorPRESIDENT AND CEO | PPurchase | +64.5K | $1.40 | +$90.5K | +94.9%132.5K after | 2 lots |
| Aug 12, 2025 (view filing) | Jun 10 | 63 daysLate | Schwartz AharonDirector | PPurchase | +129.0K | $1.60 | +$206.4K | +74.1%303.0K after | |
| Nov 19, 2025 (view filing) | Nov 18 | 1 day | Bar-Shalev AmosDirector | SSale | −168 | $1.87 | −$314.16 | −100.0%0 after | |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Bashan DrorPRESIDENT AND CEO | PPurchase | +56.0K | $1.81 | +$101.4K | +42.3%188.5K after |